Loading clinical trials...
Loading clinical trials...
A Randomized Controlled Trial on the Effectiveness of Epidermal Growth Factor-containing Ointment on the Treatment of Solar Lentigines as Adjuvant Therapy
Subjects were randomly assigned to groups for treatment with either an EGF-containing ointment (the study group) or the vehicle alone (petrolatum; the control group). The EGF ointment included recombinant human EGF (1 μg/g). Random numbers used for assignment to groups were provided by the randomization function of SAS. The subjects received one session of laser treatment with a Q-switched (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment. . The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the EGF ointment or vehicle twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
Age
20 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Kangnam Sacred Heart Hospital
Seoul, South Korea
Start Date
July 20, 2017
Primary Completion Date
September 20, 2018
Completion Date
December 26, 2018
Last Updated
January 11, 2021
40
ACTUAL participants
epidermal growth factor (EGF)-containing ointment
DRUG
Vehicle ointment
DRUG
Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser
PROCEDURE
Lead Sponsor
Hallym University Kangnam Sacred Heart Hospital
NCT06348134
NCT07222215
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions